Chronic kidney disease is a global public health problem,which can progress to end-stage kidney disease.Podocyte injury is a common pathological type of various glomerular diseases,and the incidence of proteinuria can increase with the decrease of podocyte number.The treatment of podocyte injury is still limited by complex etiology,significant side effects of immunotherapy,and late initiation of targeted non-immunosuppressive therapy.In recent years,the research on the mechanism of sodium-glucose cotransporter 2 inhibitors(SGLT2i)in chronic kidney disease had become increasingly extensive and in-depth,but there were still few reports on targeting podocytes.In this paper,the mechanism of SGLT2i against podocyte injury is reviewed,which provides a more sufficient theoretical foundation for the application of SGLT2i in the treatment of podocyte injury-related diseases.
维普
万方数据